Ebola vaccines
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVABN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Anywaine Z et al.
The Journal of Infectious Diseases 2019 Jun 5;220(1):46-56.
Safety, immunogenicity and risk–benefit analysis of rVSV- G-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions
Bache Emmanuel Bache, Martin P Grobusch & Selidji Todagbe Agnandji
Future Microbiology 2020;12(2):85-106.
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
PLoS One 2018; 13(2): e0192312.
Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone
Vaccine 2017 Jan 23;35(4):544-551.
Vaccination of contacts of Ebola virus disease survivors to prevent further transmission
The Lancet Global Health Dec 2020; 8.
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Nature Medicine 2019 Oct;25,1589–1600.
Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
The Journal of Infectious Diseases 2020; jiaa586.
Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults
The Journal of Infectious Diseases 2017 Jun 15;215(12):1789-1798.
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)
The Lancet 2017 Feb 4;389(10068):505-518.
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
The Lancet Infectious Diseases 2018 Jul;18(7):738-748.
Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea
Vaccine 2019; 37: 7171-7177.
Prior vaccination with recombinant Vesicular Stomatitis Virus – Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection
Vaccine 2020; 38: 3003–3007.
Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease
Emerg Infect Dis 2016 Jan;22(1):105–108.
Controversial Ebola vaccine trials in Ghana: a thematic analysis of critiques and rebuttals in digital news
BMC Public Health 2017 Aug 7;17(1):642.
A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?
Philos Trans R Soc Lond B Biol Sci 2017 May 26;372(1721).
Prevention of Ebola virus disease through vaccination: where we are in 2018
The Lancet 2018 Sep 1; 392(10149):787-790.
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial
JAMA 2016 Apr 19;315(15):1610-23.
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BNFilo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
The Journal of Infectious Diseases 2019 Jun 5;220(1):57-67.
Dynamics of the humoral immune response to a 6 prime-boost Ebola vaccine: quantification and 7 sources of variation
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVS-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomized, observer-blind, participant-blind, placebo-controlled, phase 2 trial
Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis
The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVΔG-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak
A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial
Last updated: